File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Partial suppression by pyridinolcarbamate of growth and necrosis of atherosclerotic lesions in swine subjected to an atherogenic regimen that produces advanced lesions

TitlePartial suppression by pyridinolcarbamate of growth and necrosis of atherosclerotic lesions in swine subjected to an atherogenic regimen that produces advanced lesions
Authors
Issue Date1979
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/yexmp
Citation
Experimental And Molecular Pathology, 1979, v. 30 n. 1, p. 85-93 How to Cite?
AbstractConflicting results have been reported in the literature on the effects of pyridinolcarbamate on the prevention of experimentally induced atherosclerosis in rabbits. In the current study the effects of pyridinolcarbamate have been tested in a swine model in which advanced atherosclerosis is produced by a combination of balloon-intimal trauma and a hyperlipidemic diet. Results were compared with those in two reference groups of swine subjected to the same atherogenic regimen - one left untreated by drugs and the other treated with hydroxyurea which is one of the antimetabolites used in cancer chemotherapy. In both drug-treated groups the intimal surface involved by atherosclerotic lesions, and the lesion area expressed as a ratio to the total medial area were significantly less than those of the untreated control group. Both drugs also significantly reduced the number of necrotic atheromatous lesions as compared to the untreated group. The mechanism of action of pyridinolcarbamate in our experimental condition is not clear at present. The demonstration of a beneficial effect of a relatively non-toxic drug such as pyridinolcarbamate seems to us to warrant carrying out further 'in depth' study of this drug.
Persistent Identifierhttp://hdl.handle.net/10722/178405
ISSN
2015 Impact Factor: 2.638
2015 SCImago Journal Rankings: 1.130
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, WMen_US
dc.contributor.authorLee, KTen_US
dc.contributor.authorThomas, WAen_US
dc.date.accessioned2012-12-19T09:47:32Z-
dc.date.available2012-12-19T09:47:32Z-
dc.date.issued1979en_US
dc.identifier.citationExperimental And Molecular Pathology, 1979, v. 30 n. 1, p. 85-93en_US
dc.identifier.issn0014-4800en_US
dc.identifier.urihttp://hdl.handle.net/10722/178405-
dc.description.abstractConflicting results have been reported in the literature on the effects of pyridinolcarbamate on the prevention of experimentally induced atherosclerosis in rabbits. In the current study the effects of pyridinolcarbamate have been tested in a swine model in which advanced atherosclerosis is produced by a combination of balloon-intimal trauma and a hyperlipidemic diet. Results were compared with those in two reference groups of swine subjected to the same atherogenic regimen - one left untreated by drugs and the other treated with hydroxyurea which is one of the antimetabolites used in cancer chemotherapy. In both drug-treated groups the intimal surface involved by atherosclerotic lesions, and the lesion area expressed as a ratio to the total medial area were significantly less than those of the untreated control group. Both drugs also significantly reduced the number of necrotic atheromatous lesions as compared to the untreated group. The mechanism of action of pyridinolcarbamate in our experimental condition is not clear at present. The demonstration of a beneficial effect of a relatively non-toxic drug such as pyridinolcarbamate seems to us to warrant carrying out further 'in depth' study of this drug.en_US
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/yexmpen_US
dc.relation.ispartofExperimental and Molecular Pathologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAorta - Metabolismen_US
dc.subject.meshAorta, Abdominal - Pathologyen_US
dc.subject.meshArteriosclerosis - Drug Therapy - Metabolism - Pathologyen_US
dc.subject.meshCalcinosisen_US
dc.subject.meshCarbamates - Therapeutic Useen_US
dc.subject.meshCholesterol - Metabolismen_US
dc.subject.meshCholesterol, Dietaryen_US
dc.subject.meshDiet, Atherogenicen_US
dc.subject.meshHydroxyurea - Therapeutic Useen_US
dc.subject.meshMaleen_US
dc.subject.meshNecrosisen_US
dc.subject.meshPyridinolcarbamate - Therapeutic Useen_US
dc.subject.meshSwineen_US
dc.titlePartial suppression by pyridinolcarbamate of growth and necrosis of atherosclerotic lesions in swine subjected to an atherogenic regimen that produces advanced lesionsen_US
dc.typeArticleen_US
dc.identifier.emailLee, WM: hrszlwm@hku.hken_US
dc.identifier.authorityLee, WM=rp00728en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0014-4800(79)90083-2-
dc.identifier.pmid421864-
dc.identifier.scopuseid_2-s2.0-0018372679en_US
dc.identifier.volume30en_US
dc.identifier.issue1en_US
dc.identifier.spage85en_US
dc.identifier.epage93en_US
dc.identifier.isiWOS:A1979GK81800007-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLee, WM=24799156600en_US
dc.identifier.scopusauthoridLee, KT=8054054000en_US
dc.identifier.scopusauthoridThomas, WA=35551799800en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats